Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Use of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This was a multicenter, randomized, open label, non inferiority clinical study. It consisted of a 24-week treatment period (0-24 weeks) and a 24-week extension period (25-48 weeks). About 160 patients which had received Recombinant human erythropoietin (rHuEPO) or Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) treatment were randomized in a 1:1 ratio to receive Pegmolesatide with different administration regimens.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

⁃ Aged ≥18 years and ≤80 years, regardless of gender;

• Body weight ≥45 kg; Body Mass Index (BMI) ≥18.5 kg/m²;

• Diagnosed with chronic kidney disease (CKD) complicated by renal anemia, with an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m² before randomization (GFR estimation using the CKD-EPI formula); Undergoing continuous treatment with rHuEPO or HIF-PHI for ≥2 weeks before randomization;

• Hemoglobin (Hb) level measured within 7 days before randomization ≥70 g/L and \< 110 g/L;

• Understanding the study procedures and voluntarily signing the Informed Consent Form (ICF)

Locations
Other Locations
China
Poster
RECRUITING
Dalian
Contact Information
Primary
Hongli Lin, M.D.
linhongli@vip.163.com
13332268576
Backup
Jilin Chen, M.D.
18098875658
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2027-12
Participants
Target number of participants: 160
Treatments
Experimental: Pegmolesatide utilization regimen group
initial phase:Body weight ≤60kg, initial dose 2.0mg; Body weight \> 60kg, initial dose 3.2mg, once every 4 weeks by subcutaneous injection.~Adjustment phase:based on Hb levels and its changes every 4 weeks, once a month by subcutaneous injection.
Active_comparator: Pegmolesatide standard medication regimen group
initial phase:0.04mg/kg body weight, once every 4 weeks by subcutaneous injection.~Adjustment phase:based on Hb levels and its changes every 4 weeks, once a month by subcutaneous injection.
Related Therapeutic Areas
Sponsors
Collaborators: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Leads: The First Affiliated Hospital of Dalian Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials